Peptide-conjugated antisense therapy takes a skip ahead. - National Genomics Data Center (CNCB-NGDC)

Advanced Search

Peptide-conjugated antisense therapy takes a skip ahead.

Dominic J Wells

Author Information

Dominic J Wells: Department of Cellular and Molecular Neuroscience, Imperial College London, London, UK. d.wells@imperial.ac.uk

PMID: 18725878 DOI: 10.1038/mt.2008.157

No abstract text available.

Humans

Neoplasms

Oligonucleotides, Antisense

Peptide Fragments

Oligonucleotides, Antisense

Peptide Fragments

Comment Journal Article

Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide.Peptide-oligonucleotide hybrids in antisense therapy.A nine carbon homologating system for skip-conjugated polyenes.Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo.Eukaryotic antisense ahead of its time.Cellular delivery and antisense effects of peptide nucleic acid conjugated to polyethyleneimine via disulfide linkers.Purification of noncoding RNA and bound proteins using FLAG peptide-conjugated antisense-oligonucleotides.Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.